Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
25 nov. 2020 08h12 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
20 oct. 2020 08h00 HE
|
Interpace Biosciences, Inc.
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
21 juil. 2020 06h05 HE
|
Interpace Biosciences, Inc.
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
13 janv. 2020 06h55 HE
|
Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
17 déc. 2019 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
04 nov. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Interpace Named to ‘Most Admired Companies’ List
15 oct. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The...
Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans
30 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
In-Network Access for Thyroid Assays for More than 5 Million Members PARSIPPANY, NJ, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it...
Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference
18 sept. 2019 06h55 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming...
Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update
13 août 2019 08h15 HE
|
Interpace Diagnostics Group, Inc.
Second Quarter Revenue Grew 14% Over the Prior Year and 19% Year to Date Over the Prior Year Acquired Growing BioPharma Services Business Net Revenue Guidance Increased Conference Call and...